Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kadcyla Positioned For Wide Use In Metastatic Breast Cancer

Executive Summary

Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.


Related Content

Surprise! Roche Says It Will Not Pursue Herceptin Patents In India
Roche CEO Severin Schwan Fueled By Innovation, Emerging Markets: An Interview With PharmAsia News
Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
Roche Third-Quarter Pipeline Adjustments Include Advancements, Delays
With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up
Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts